The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).
 
Sara A. Hurvitz
Honoraria - Genentech/Roche
Research Funding - Amgen (Inst); Bayer (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Lilly; Novartis; Pfizer
 
Miguel Martin
Consulting or Advisory Role - Amgen; Lilly; Novartis; Pfizer; Roche/Genentech
Research Funding - Novartis (Inst)
 
William Fraser Symmans
Stock and Other Ownership Interests - Ions Pharmaceuticals; Nuvera Biosciences
Honoraria - Affymetrix
Patents, Royalties, Other Intellectual Property - Nuvera Biosciences
Travel, Accommodations, Expenses - Abbvie
 
Kyung Hae Jung
Research Funding - Eisai
 
Chiun-Sheng Huang
Honoraria - Novartis; Roche
Consulting or Advisory Role - Roche
Research Funding - Abbvie; Amgen; AstraZeneca; Biomarin; Boehringer Ingelheim; Genentech; Lilly; Novartis; OBI Pharma; Pfizer; Roche
 
Alastair Mark Thompson
No Relationships to Disclose
 
Nadia Harbeck
No Relationships to Disclose
 
Vicente Valero
Research Funding - Roche/Genentech
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Hans Wildiers
Consulting or Advisory Role - Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Roche
 
Karen Afenjar
Travel, Accommodations, Expenses - Roche
 
Rodrigo Fresco
Travel, Accommodations, Expenses - Roche/Genentech
 
Hans-Joachim Helms
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Jin Xu
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Yvonne Gail Lin
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Consulting or Advisory Role - Advaxis; ClearPath Development Company
Research Funding - Array BioPharma; Astex Pharmaceuticals
Travel, Accommodations, Expenses - Array BioPharma
 
Joseph A. Sparano
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - AstraZeneca; Celgene; Curis; Eisai; Genentech/Roche; Johnson & Johnson; Novartis; Sanofi
Research Funding - Merck (Inst)
 
Dennis J. Slamon
Leadership - Biomarin
Stock and Other Ownership Interests - Pfizer
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer